BiotechTube

Foralumab

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection

Trial Timeline

Apr 30, 2022 → Dec 30, 2022

NCT ID
NCT04983446

About Foralumab

Foralumab is a phase 2 stage product being developed by Tiziana Life Sciences for Covid19. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04983446. Target conditions include Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection.

What happened to similar drugs?

4 of 16 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (9)
❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
✅Icosapent ethylAmarin CorporationApproved
❌BaricitinibEli LillyPhase 3
🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
✅bamlanivimabEli LillyApproved
🔄Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3
🔄Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06292923Phase 2Recruiting
NCT05028946Phase 1Withdrawn
NCT04983446Phase 2Withdrawn

Competing Products

20 competing products in Covid19

See all competitors
ProductCompanyStageHype Score
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Icosapent ethylAmarin CorporationApproved
25
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
DS-5670a + PlaceboDaiichi SankyoPhase 1/2
32
Pegylated Interferon-α2bZydus LifesciencesPhase 2
27
BaricitinibEli LillyPhase 3
32
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
40
bamlanivimabEli LillyApproved
35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222AstraZenecaPhase 1
25
Sacubitril / Valsartan Oral Tablet [Entresto] + PlaceboNovartisPhase 1/2
32
PirfenidoneRochePre-clinical
26
Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3
40
RemdesivirGilead SciencesPre-clinical
26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3
40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3
36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 VaccinePfizerPre-clinical
26
Tofacitinib 10 mg + PlaceboPfizerPhase 3
40
BNT162b2PfizerPhase 2
35